Company demonstrated encouraging clinical efficacy with 29% ORR at higher dose, improved safety profile with minimal discontinuations and no severe adverse events, strong cash position extending runway to early 2028, multiple ongoing collaborations with major pharma partners (Sanofi, Roche, Exelixis), and clear regulatory pathway with FDA Fast Track designation and Project Optimus alignment. Net loss improved significantly year-over-year from $33.4M to $17.6M.
Also mentions ADAG
Articles that tag ADAG but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
